11 Oct New healthcare board in Denmark provides access to main players
Clairfield International in Denmark has assembled an expert healthcare board, increasing the number and breadth of healthcare executives who serve as senior advisors to Clairfield. Headed by partner Dr. Anne Sofie (“Fie”) Astrup, the advisory board of leading figures in the Danish healthcare industry analyze the validity of projects, perform outreach to multinational companies in pharmaceuticals and life sciences, and deliver unique insight and perspective.
Fie trained as a cardiovascular surgeon and holds a doctorate of medical science based on her clinical research into diabetes and cardiovascular complications. She received an MBA from Copenhagen Business School. Fie established the scientific board with a focus on specific fields that Danish pharmaceutical companies typically invest in. Members of the advisory board share knowledge of their specific fields and have large networks that can be tapped into for relevant projects.
One such senior advisor is Jan Leschly, a well-known figure in the pharmaceutical industry. Jan served as CEO of SmithKline Beecham PLC, as president and COO at Squibb Corporation, and as president of Novo’s pharmaceuticals division. In 2000 Jan founded Care Capital where he continues as managing partner in addition to his board appointments at APM Holding and the APM – Maersk Group.
Fie is a member of Clairfield International’s healthcare practice of more than 50 M&A professionals who maintain relationships with key participants in the healthcare segment. Healthcare is a very active sector for Clairfield International with many closed deals particularly in residential care and the dental sector. Recent Clairfield healthcare transactions include Stichting Fundis’ acquisition of a Rotterdam geriatric and rehabilitation center, and the sale by Groupe Nadia of Prodont Holliger, a manufacturer of dental instruments, to Acteon, backed by Bridegepoint Capital. Clairfield’s healthcare group is led by Jack Helm and Andreas Piechotta, and recently met in Amsterdam under the auspices of the Clairfield Netherlands healthcare group, led by Dagmar Enklaar.
“The healthcare market in Denmark, like that of other parts of the world, is on the rise”, says Fie. “Denmark has a model of private/public research collaboration which makes the market interesting for investors, and many of the world´s leading pharmaceuticals are centered around Copenhagen, including Novo Nordisk, LEO, Lundbeck, Coloplast, and Radiometer.”